2016 Progress Report
In June 2015, the OHSU Knight Cancer Institute announced to the world that it had achieved a $500 million fundraising challenge set by Nike co-founder Phil Knight and his wife, Penny, raising $1 billion for cancer research.

We plan to allocate the billion dollars in the following ways:

- **20%** will be used on the construction and development of the Knight Cancer Research Building and new cancer clinical facilities on the South Waterfront.
- **25%** will be placed in an endowment for future ongoing income.
- **55%** will be divided over the next ten years to be used in our fight against cancer.

In an effort to end cancer as we know it, much of the past year has focused on laying the groundwork for new and expanded programs, improved facilities and more collaborations.
The state of Oregon generously provided the Knight Cancer Institute with financial backing for the future Knight Cancer Research Building (KCRB) in Portland’s South Waterfront District.

The KCRB will play a crucial role in expanding the Knight’s capacity for cancer research. Four out of the building’s seven floors will be specifically devoted to cancer research, including early detection.

Groundbreaking on the Knight’s new buildings

Construction is currently underway with opening scheduled for JULY 2018.
In March 2016, the OHSU Knight Cancer Institute announced Sadik Esener, Ph.D., had joined as director of the Center for Early Detection Research and Wendt Family Endowed Chair in Early Cancer Detection.

As a nanotechnology expert, engineer and computer scientist, he will bring an engineering systems-based approach to the role by integrating state-of-the-art technologies.

Esener’s appointment launches an ambitious plan to build a program filling one of the biggest unmet needs in cancer treatment today: detecting lethal cancers early, when they are most treatable.

Approximately 25 scientists and 200-300 lab staff will be hired to help build this program.

In August 2015, OHSU and Intel unveiled the Collaborative Cancer Cloud precision medicine analytics platform.

The goal is to enable doctors anywhere to access records of millions of cancer patients, including a patient’s genomic, imaging and clinical data — allowing them to design the most effective treatments and potentially life-saving discoveries.

By 2025, patients could have their cancer cells analyzed through genome sequencing and imaging and have a precision treatment plan tailored to their specific cancer within 24 hours.
An early detection of cancer conference was held in Portland in June of 2016, the first of a series of annual conferences planned through this collaboration.

In December 2015, Cancer Research UK, one of the largest funders of cancer research globally, and the Knight Cancer Institute formed an international collaboration to accelerate research in the field of early detection.

This collaboration is part of the Knight Cancer Institute’s long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods and enhance the uptake and accuracy of screening.

In October 2015, Immunovia AB and the Knight Cancer Institute formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer and to create new protein-based tests for cancer.

The test, called IMMray™ PanCan-d, analyzes a patient’s immune system for early signs of disease. If validated, this test would be the first blood-based test available for early and specific diagnosis of pancreatic cancer, and may provide physicians with actionable information early enough for the cancer to be removed surgically.

The Beat AML project is delivering a plethora of new drug candidates and treatment ideas for acute myeloid leukemia (AML), the most frequently diagnosed leukemia in adults.

In the two years since the Beat AML initiative was launched, more than 450 samples have been collected at OHSU and other centers including the Huntsman Cancer Institute at the University of Utah, Stanford University, Sylvester Comprehensive Cancer Center at the University of Miami, UT Southwestern Medical Center and the University of Colorado Cancer Center.

Collaborations

Cancer Research UK

In December 2015, Cancer Research UK, one of the largest funders of cancer research globally, and the Knight Cancer Institute formed an international collaboration to accelerate research in the field of early detection.

This collaboration is part of the Knight Cancer Institute’s long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods and enhance the uptake and accuracy of screening.

Immunovia

In October 2015, Immunovia AB and the Knight Cancer Institute formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer and to create new protein-based tests for cancer.

The test, called IMMray™ PanCan-d, analyzes a patient’s immune system for early signs of disease. If validated, this test would be the first blood-based test available for early and specific diagnosis of pancreatic cancer, and may provide physicians with actionable information early enough for the cancer to be removed surgically.

Beat AML

The Beat AML project is delivering a plethora of new drug candidates and treatment ideas for acute myeloid leukemia (AML), the most frequently diagnosed leukemia in adults.

In the two years since the Beat AML initiative was launched, more than 450 samples have been collected at OHSU and other centers including the Huntsman Cancer Institute at the University of Utah, Stanford University, Sylvester Comprehensive Cancer Center at the University of Miami, UT Southwestern Medical Center and the University of Colorado Cancer Center.
The Knight Cancer Institute continues to grow clinical trials capacity both on the main OHSU campus and throughout the state.

In 2015, 679 Oregon residents consented to interventional clinical research studies associated with the OHSU Knight Cancer Institute. These research subjects represented 29 of the 36 Oregon counties.

Knight Cancer Network
Established in October 2015, the OHSU Knight Cancer Network collaborates with community hospitals, health care organizations, and physicians across the state to 1) Reduce cancer risks for Oregonians and 2) Improve clinical outcomes for cancer patients. The network will also offer resources and support to patients in directing patients to appropriate clinical trials.

Community Partnership Program
In October 2014, The OHSU Knight Cancer Institute established the Community Partnership Program. The program provides funding and expertise to organizations addressing community-identified needs related to cancer including skills development training, technical assistance and networking opportunities for grantees.

After three rounds of funding, 43 PROJECTS have been awarded, benefitting 32 of the state’s 36 counties. The funded projects represent the full range of cancer-related needs from prevention through survivorship.

In 2015, 679 Oregon residents consented to interventional clinical research studies associated with the OHSU Knight Cancer Institute. These research subjects represented 29 of the 36 Oregon counties.

The Knight Cancer Institute's community outreach continues to be an important presence within Oregon communities. Events like May’s War on Skin Cancer outreach event made significant strides for future cancer research with 501 new saliva samples collected and 371 new sign-ups for the Melanoma Community Registry.
In addition to community events, OHSU faculty delivered 88 EDUCATIONAL TALKS about cancer to health care professionals (including Continuing Medical Education accredited talks), patients/families, and the general public.

Knight Cancer Institute Community Health Educators partnered with three Central Oregon schools to engage 855 STUDENTS in interactive, cancer prevention research activities. Educators participated in four community events disseminating sun safety education to over 980 community members in Jefferson, Crook and Deschutes counties.

Patients are the most important part of our mission. Delivering high-quality, effective cancer care to patients is the backbone of the Knight Cancer Institute.

In the last year, 2,079 PATIENTS have been treated by the Knight Cancer Institute.

* Inpatient Adult Oncology Patients from June 2015 – May 2016
In the past twelve months, the Knight Cancer Institute continued to support research among its members, and papers were published in such prestigious journals as Cell, Nature, The New England Journal of Medicine, Lancet, and many more.